Navigation Links
DURECT Corporation Announces Third Quarter 2010 Financial Results
Date:11/3/2010

hold worldwide rights.TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to seven days from a single application.•

ORADUR-ADHD Program.  In July 2010, we commenced a Phase I clinical trial in this program with multiple formulations. ORADUR-ADHD applies our proprietary ORADUR technology to a leading active pharmaceutical ingredient for the treatment of attention deficit disorder (ADHD). Under an agreement with Orient Pharma, we are collaborating to perform a clinical development program through a Phase II study intended to produce a data package that will support later stage development of the drug candidate and subsequent licensing by DURECT. We are responsible for formulation and study design of the pre-defined clinical program, which Orient Pharma will fund and execute.•

Therapeutic Discovery Tax Grant.  In October 2010, DURECT was notified that we have been awarded grants totaling $733,438 under the Patient Protection and Affordable Care Act of 2010 for three qualifying therapeutic discovery projects; we expect to receive this funding in the fourth quarter of 2010.Earnings Conference CallA live audio webcast of a conference call to discuss third quarter 2010 results will be broadcast live over the internet at 4:30 p.m. Eastern Time on November 3 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT CorporationDURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic disea
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
2. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
3. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
4. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
5. DURECT to Present at the Jefferies Global Life Sciences Conference
6. DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
7. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
8. DURECT to Present at the Barclays Capital Global Healthcare Conference
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
11. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... prospects for leading ophthalmic drug companies  What ... pharma ophthalmic industry ? Visiongain,s brand new report ... opportunities and prospects there. Our 242-page report ... lucrative areas in the industry and the future market ...
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:3/30/2015)... Considered to be the best assessment tool for ... community, this next generation of the IT Audit ... data and frameworks with virtually endless possibilities. These new ... logic features are a technological force to be reckoned ... “The IT Audit Machine is just one of the ...
(Date:3/30/2015)... 2015 A new recruitment site has ... for their next career move. , Millions of new ... for those with skills in the booming data and ... is a jobs aggregator, pulling in opportunities from both ... them individually to help candidates find suitable big data ...
(Date:3/30/2015)... March 30, 2015 TherapySites, ... for mental health professionals, announced today its affiliation ... TherapySites to extend their online marketing solutions to ... , "As we continue to see advancements in ... the Internet effectively in order to succeed,” said ...
(Date:3/30/2015)... Developing new treatments for Diabetes Type 2 ... models that recapitulate only some subset of the specific ... , A company that specializes in developing and manufacturing ... has created iPSC-derived cardiomyocytes (heart muscle cells), which have ... vitro models of Diabetes Type 2. The development process ...
(Date:3/30/2015)... March 30, 2015 Bunion Bootie ... Buy them for family members, friends...and yourself and save. For ... can save an additional 10%, on top of discounts already ... code "EasterPR" at checkout. The more Bunion Booties purchased, the ... spacers, and bunion pads, Bunion Bootie can be worn comfortably ...
Breaking Medicine News(10 mins):Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:TherapySites (Websites for Therapists) Partners with BehaveNet 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2
... primates points to possible weapon against human infection with ... Researchers have successfully tested several Ebola vaccines in monkeys ... vaccine for one of the world,s deadliest diseases. ... overlooked. We are seeing more and more naturally occurring ...
... The Palace was the backdrop,for technology,s royalty last ... "Best in Show" at the 2008 NJ Venture Conference., ... Succeed" and,Switch2Health of New Brunswick took the prize for ... crowd of more than 500 entrepreneurs,and investors looking for ...
... and Chapel Hill, N.C. March 31, 2008 - ... Journal of Medicine, which concluded that lung transplants were ... the latest issue of Pediatric Transplantation refute the conclusions ... flawed. , According to two rebuttals published in the ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... on ... NEW YORK, March 31 For expectant parents, choosing ... significant decision. But,there are many things that go on behind ... properly in order to ensure a,positive patient experience and a ...
... Lowering the blood pressure of elderly patients could cut ... of cardiovascular events by a third, according to a ... American College of Cardiology in Chicago and published simultaneously ... 3,845 patient Hypertension in the Very Elderly Trial (HYVET), ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 3Health News:Lung transplants not dangerous for children with cystic fibrosis, after all 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3
LB Agar plates with 10mM Magnesium Sulfate....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... Molecular Biology Buffers are ready-to-use solutions ideal ... applications. Each reagent is prepared with 18 ... filter, and filled into sterile bottles., ... control standards to ensure lot-to-lot consistency. ...
Medicine Products: